Johnson & Johnson's (JNJ) innovative therapy combining Tecvayli (teclistamab) and Darzalex (daratumumab) has been awarded a national priority voucher under an FDA Commissioner pilot program. This designation accelerates the review process for therapies that meet critical medical needs or bolster U.S. supply chain resilience. The Tec-Dara combination is the 16th treatment to receive this recognition, with phase 3 data indicating significant improvements in progression-free and overall survival for patients with multiple myeloma who have undergone one to three previous therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.